Catalog No.
YVV08802
Expression system
E. coli
Species
Human papillomavirus type 16
Protein length
Confidential
Predicted molecular weight
76.45 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
A0A161GUX4
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Major capsid protein L1, L1
All-atom MD simulations of the HPV16 capsid., PMID:40475506
HPV16 neutralizing monoclonal antibodies show evidence for common developmental pathways and public epitopes., PMID:40236113
A novel fluorescence immunoassay for the quantitative detection of HPV16 L1 antibodies in human serum samples using ZnCdSe/ZnS quantum dot-labeled antibodies., PMID:40197040
Genetic analysis of HPV-16 L1 gene mutations and computational screening of therapeutic inhibitors for cervical cancer treatment., PMID:40192871
Molecular epidemiology of human papillomavirus variants in cervical cancer in India., PMID:39913513
Bioinspired synthesis of virus-like particle-templated thin silica-layered nanocages with enhanced biocompatibility and cellular uptake as drug delivery carriers., PMID:39642678
Detection of HPV 16 and 18 L1 genes by a nucleic acid amplification-free electrochemical biosensor powered by CRISPR/Cas9., PMID:39608317
[A fluorescence immunochromatography method for detection of human papillomavirus type 16 E6 and L1 proteins]., PMID:39584350
Glycan-induced structural activation softens the human papillomavirus capsid for entry through reduction of intercapsomere flexibility., PMID:39572555
Design and antiviral assessment of a panel of fusion proteins targeting human papillomavirus type 16., PMID:39453911
Comparative Analysis of HPV16 Variants in the Untranslated Regulatory Region, L1, and E6 Genes among Vaccinated and Unvaccinated Young Women: Assessing Vaccine Efficacy and Viral Diversity., PMID:39339857
Heterogeneity of HPV16 virus-like particles indicates a complex assembly energy surface., PMID:39276669
Engineering of Recombinant Human Papillomavirus 16 L1 Protein for Incorporation with para-Azido-L-Phenylalanine., PMID:39155395
Immunoinformatics approach for design novel multi-epitope prophylactic and therapeutic vaccine based on capsid proteins L1 and L2 and oncoproteins E6 and E7 of human papillomavirus 16 and human papillomavirus 18 against cervical cancer., PMID:39039819
Prevalence of HPV16 L1 protein in oral biopsies: A diagnostic study from Ecuador., PMID:39018933
Genetic variability of human papillomavirus type 18 based on E6, E7 and L1 genes in central China., PMID:38970084
The Micro-Immunotherapy Medicine 2LPAPI® Displays Immune-Modulatory Effects in a Model of Human Papillomavirus Type-16 L1-Protein Capsid-Treated Human Peripheral Blood Mononuclear Cells and Antiproliferative Effects in a Model of Cervical Cancer Cells., PMID:38611099
A validated polyclonal antiserum-based immunoassay for assessment of HPV 16 L1 relative potency., PMID:38340596
Interaction studies between human papillomavirus virus-like particles and laminin 332 by affinity capillary electrophoresis assisted by bio-layer interferometry., PMID:38199121
Nano-Sized Chimeric Human Papillomavirus-16 L1 Virus-like Particles Displaying Mycobacterium tuberculosis Antigen Ag85B Enhance Ag85B-Specific Immune Responses in Female C57BL/c Mice., PMID:37896900
Alum and a TLR7 agonist combined with built-in TLR4 and 5 agonists synergistically enhance immune responses against HPV RG1 epitope., PMID:37798448
Crystal Structures of Plk1 Polo-Box Domain Bound to the Human Papillomavirus Minor Capsid Protein L2-Derived Peptide., PMID:37684534
Design of a Synthetic Long Peptide Vaccine Targeting HPV-16 and -18 Using Immunoinformatic Methods., PMID:37513985
Chimeric Human Papillomavirus-16 Virus-like Particles Presenting HIV-1 P18I10 Peptide: Expression, Purification, Bio-Physical Properties and Immunogenicity in BALB/c Mice., PMID:37175776
A Cas12a ortholog with distinct TTNA PAM enables sensitive detection of HPV16/18., PMID:37159673
Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination., PMID:36922512
Human papilloma virus-16-specific CD8+ T-cell expansions characterize different clinical forms of lichen planus and not lichen sclerosus et atrophicus., PMID:36922453
Critical Residues Involved in the Coassembly of L1 and L2 Capsid Proteins of Human Papillomavirus 16., PMID:36815785
Mutation Profile of HPV16 L1 and L2 Genes in Different Geographic Areas., PMID:36680181
Chimeric Human Papillomavirus-16 Virus-like Particles Presenting P18I10 and T20 Peptides from HIV-1 Envelope Induce HPV16 and HIV-1-Specific Humoral and T Cell-Mediated Immunity in BALB/c Mice., PMID:36679860
Serologic Response to Human Papillomavirus Genotypes Among Unvaccinated Women: Findings From the HITCH Cohort Study., PMID:36322543
Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development., PMID:36263027
Investigation of the Presence of DNA of Highly Pathogenic Human Papillomaviruses in Water Bodies of the Lake Baikal Natural Territory., PMID:35932447
Non-Functionalized Gold Nanoparticles Inhibit Human Papillomavirus (HPV) Infection., PMID:35886898
RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer., PMID:35703545
Anti-L1 antibody-bound HPV16 pseudovirus is degraded intracellularly via TRIM21/proteasomal pathway., PMID:35619167
Human Papillomavirus Minor Capsid Protein L2 Mediates Intracellular Trafficking into and Passage beyond the Endoplasmic Reticulum., PMID:35608352
Genetic variability in minor capsid protein (L2 gene) of human papillomavirus type 16 among Indian women., PMID:35552511
Hypochlorous acid as a disinfectant for high-risk HPV: Insight into the mechanism of action., PMID:35277984
Detecting Human Papillomavirus Type 16 in Cervical Cancer Patients with Molecular Variation of Gene L1 in Riau Province Indonesia., PMID:35092375
HPV16 Entry into Epithelial Cells: Running a Gauntlet., PMID:34960729
Identification of heterogenous nuclear ribonucleoproteins (hnRNPs) and serine- and arginine-rich (SR) proteins that induce human papillomavirus type 16 late gene expression and alter L1 mRNA splicing., PMID:34860285
Germline determinants of humoral immune response to HPV-16 protect against oropharyngeal cancer., PMID:34642315
Attenuated Salmonella carrying plasmid co-expressing HPV16 L1 and siRNA-E6 for cervical cancer therapy., PMID:34635698
Human Papillomavirus Vaccines., PMID:34590141
Designing a therapeutic and prophylactic candidate vaccine against human papillomavirus through vaccinomics approaches., PMID:34547435
Immunological responses and anti-tumor effects of HPV16/18 L1-L2-E7 multiepitope fusion construct along with curcumin and nanocurcumin in C57BL/6 mouse model., PMID:34516991
Human papillomavirus 16 L1 gene methylation as a potential biomarker for predicting anal intraepithelial neoplasia in men who have sex with men (MSM)., PMID:34469465
In Silico Design and Immunological Studies of Two Novel Multiepitope DNA-Based Vaccine Candidates Against High-Risk Human Papillomaviruses., PMID:34308516
Mutation Profiles, Glycosylation Site Distribution and Codon Usage Bias of Human Papillomavirus Type 16., PMID:34209097
For research use only. Not for human or drug use.
